<DOC>
	<DOC>NCT00638859</DOC>
	<brief_summary>The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5-7 days in children with community-acquired pneumonia (CAP). Secondary objectives are to assess Pharmacokinetics, Efficacy and Acceptability of telithromycin 20 mg/kg qd for 5-7 days in children with CAP.</brief_summary>
	<brief_title>Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Subjects who are weighing 40 kg or less. If female, premenarchal status is required. Subjects who are diagnosed with CAP based on chest Xray showing the presence of a new infiltrate, clinical symptoms, and laboratory findings. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Community-Acquired pneumonia</keyword>
	<keyword>CAP</keyword>
	<keyword>children</keyword>
	<keyword>Child</keyword>
</DOC>